Lettmann Jason sold $4K of ALXO
Lettmann Jason (CHIEF EXECUTIVE OFFICER) sold 2,230 shares of ALX ONCOLOGY HOLDINGS INC (ALXO) at $1.93 on 2026-08-17.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CEO’s open-market sale details (shares, price, total value, and post-transaction holdings).
Market read
Traders may briefly reassess sentiment around ALXO based on the CEO’s sale, but there is no fundamental update in the text.
What to watch
The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on total compensation, prior sales cadence, or remaining option/RSU overhang.
Background
The article is a SEC Form 4 insider transaction disclosure for ALX Oncology Holdings Inc.
Ticker impact
ALXO CEO Jason Lettmann filed a Form 4 open-market sale of 2,230 shares at $1.93 on 2026-08-17.
Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.
The filing is a routine insider transaction with no 10b5-1 plan stated and no accompanying company-specific operational or financial catalyst in the text.
Market effects
No sector read-through is provided beyond a single-company insider sale.
None indicated.
None indicated.
Counterpoint
Insider sales can be driven by diversification, taxes, or scheduled liquidity needs, so the signal may be weaker than traders assume.
Key entities
- issuerALX Oncology Holdings Inc
Company whose CEO insider sale is disclosed via SEC Form 4.
- insiderLettmann Jason
Chief Executive Officer and reporting person who sold shares.